Status:

COMPLETED

Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)

Lead Sponsor:

Eli Lilly and Company

Collaborating Sponsors:

Boehringer Ingelheim

Conditions:

Urinary Incontinence, Stress

Eligibility:

FEMALE

18+ years

Phase:

PHASE3

Brief Summary

The study evaluates the effectiveness of duloxetine in reducing urinary incontinence occurrences in women due to physical stress(e.g. stomach pressure on bladder). Incontinence is the inability to con...

Eligibility Criteria

Inclusion

  • female outpatients \> or = 18 years of age
  • experience episodes of stress urinary incontinence
  • must have an educational level and degree of understanding English
  • are free of urinary tract infections
  • can use the toilet independently

Exclusion

  • any in or outpatient surgery in the last six months
  • suffer from severe constipation
  • extension of any internal organs beyond vaginal opening
  • currently breastfeeding
  • any nervous diseases affecting normal urinary function

Key Trial Info

Start Date :

September 1 2003

Trial Type :

INTERVENTIONAL

End Date :

May 1 2006

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT00190827

Start Date

September 1 2003

End Date

May 1 2006

Last Update

January 26 2007

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559 OR 1-317-615-4559) Mon-Fri from 9am to 5pm Eastern time(UTC/GMT - 5 hours, EST) or speak with your personal physician

Rio de Janeiro, Brazil, 20551-030

2

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559 or 1-317-615-4559) Mon-Fri from 9am to 5pm Eastern time(UTC/GMT - 5 hours, EST) or speak with your personal physician

Québec, Quebec, Canada, Quebec G1S 2L6

3

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559 OR 1-317-615-4559) Mon-Fri from 9am to 5pm Eastern time(UTC/GMT - 5 hours, EST) or speak with your personal physician

Paris, France, 75651

4

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559 OR 1-317-615-4559) Mon-Fri from 9am to 5pm Eastern time(UTC/GMT - 5 hours, EST) or speak with your personal physician

Mainz, Germany, 55131